Dermatology COVID-19 Registries: Updates and Future Directions

Esther E. Freeman; Grace C. Chamberlin; Devon E. McMahon; George J. Hruza; Dmitri Wall; Nekma Meah; Rodney Sinclair; Esther A. Balogh; Steven R. Feldman; Michelle A. Lowes; Angelo V. Marzano; Haley B. Naik; Leslie Castelo-Soccio; Irene Lara-Corrales; Kelly M. Cordoro; Satveer K. Mahil; Christopher E. M. Griffiths; Catherine H. Smith; Alan D. Irvine; Phyllis I. Spuls; Carsten Flohr; Lars E. French

doi:https://doi.org/10.1016/j.det.2021.05.013

Dermatology COVID-19 Registries: Updates and Future Directions

Esther E. Freeman, Grace C. Chamberlin, Devon E. McMahon, George J. Hruza, Dmitri Wall, Nekma Meah, Rodney Sinclair, Esther A. Balogh, Steven R. Feldman, Michelle A. Lowes, Angelo V. Marzano, Haley B. Naik, Leslie Castelo-Soccio, Irene Lara-Corrales, Kelly M. Cordoro, Satveer K. Mahil, Christopher E. M. Griffiths, Catherine H. Smith, Alan D. Irvine, Phyllis I. SpulsCarsten Flohr, Lars E. French

Research output: Contribution to journal › Review article › Academic › peer-review

9 Citations (Scopus)

Original language	English
Pages (from-to)	575-585
Number of pages	11
Journal	Dermatologic clinics
Volume	39
Issue number	4
DOIs	https://doi.org/10.1016/j.det.2021.05.013
Publication status	Published - 1 Oct 2021

Keywords

Atopic dermatitis
COVID-19
Dermatology
Global health
Hidradenitis suppurativa
Psoriasis
Registry
SARS-CoV-2

Access to Document

https://doi.org/10.1016/j.det.2021.05.013

Cite this

Freeman, E. E., Chamberlin, G. C., McMahon, D. E., Hruza, G. J., Wall, D., Meah, N., Sinclair, R., Balogh, E. A., Feldman, S. R., Lowes, M. A., Marzano, A. V., Naik, H. B., Castelo-Soccio, L., Lara-Corrales, I., Cordoro, K. M., Mahil, S. K., Griffiths, C. E. M., Smith, C. H., Irvine, A. D., ... French, L. E. (2021). Dermatology COVID-19 Registries: Updates and Future Directions. Dermatologic clinics, 39(4), 575-585. https://doi.org/10.1016/j.det.2021.05.013

@article{4e0d714a1b1149f28b17769bb7da0ebd,

title = "Dermatology COVID-19 Registries: Updates and Future Directions",

keywords = "Atopic dermatitis, COVID-19, Dermatology, Global health, Hidradenitis suppurativa, Psoriasis, Registry, SARS-CoV-2",

author = "Freeman, {Esther E.} and Chamberlin, {Grace C.} and McMahon, {Devon E.} and Hruza, {George J.} and Dmitri Wall and Nekma Meah and Rodney Sinclair and Balogh, {Esther A.} and Feldman, {Steven R.} and Lowes, {Michelle A.} and Marzano, {Angelo V.} and Naik, {Haley B.} and Leslie Castelo-Soccio and Irene Lara-Corrales and Cordoro, {Kelly M.} and Mahil, {Satveer K.} and Griffiths, {Christopher E. M.} and Smith, {Catherine H.} and Irvine, {Alan D.} and Spuls, {Phyllis I.} and Carsten Flohr and French, {Lars E.}",

note = "Funding Information: Dr L.E. French is president of the ILDS. Dr E.E. Freeman is principal investigator of the AAD/ILDS COVID-19 Dermatology Registry. The ILDS provides financial support for the AAD/ILDS registry. Dr E.E. Freeman is an author for UpToDate. Drs S.R. Feldman, C.E.M. Griffiths, S.K. Mahil, H.B. Naik, and C.H. Smith have received funding or support from and Drs L.E. French, A.D. Irvine, and P.I. Spuls have been consultants for AbbVie; Dr M.A. Lowes has served on the advisory board for AbbVie. Drs S.R. Feldman, L.E. French, C.E.M. Griffiths, S.K. Mahil, R. Sinclair, and C.H. Smith have received funding or support from Novartis. Drs S.R. Feldman, C.E.M. Griffiths, R. Sinclair, C.H. Smith, and D. Wall have received funding from Pfizer. Drs S.R. Feldman, S.K. Mahil, and C.H. Smith have received funding from and Drs A.D. Irvine and P.I. Spuls have been consultants for Sanofi. Drs S.R. Feldman, C.E.M. Griffiths, A.D. Irvine, S.K. Mahil, R. Sinclair, and D. Wall have received funding or honoraria from Eli Lily; Drs S.R. Feldman, L.E. French, C.E.M. Griffiths, S.K. Mahil, R. Sinclair, and D. Wall have received funding or honoraria from Janssen. Drs S.R. Feldman and C.E. M. Griffiths have received funding or support from BMS, Almirall, Amgen, Galderma, LEO Pharma, Stiefel GSK, and Sun Pharmaceuticals. Drs C.E.M. Griffiths and S.K. Mahil have received funding or support from Celgene and UCB Pharma. Dr C.E.M. Griffiths has received honoraria and/or research grants from MSD and Sandoz. Dr S.R. Feldman received research, speaking and/or consulting support from Alvotech, Boehringer Ingelheim, Mylan, Ortho Dermatology, Samsung, Menlo, Helsinn, Arena, Forte, Merck, Regeneron, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. Dr S.R. Feldman is founder and majority owner of www.DrScore.com and is founder and part owner of Causa Research, a company dedicated to enhancing patients? adherence to treatment. Dr L.E. French received speaking and/or consulting support from Galderma, Amgen, Leo Pharma, Biotest, and Pincell Srl. Dr H.B. Naik has received consulting fees from 23andme, Abbvie, and DAVA Oncology and advisory board fees from Boehringer Ingelheim and is an investigator for Pfizer. She also is an associate editor for JAMA Dermatology. Dr M.A. Lowes has served on the advisory boards for Abbvie, InflaRx, Janssen, and Viela Bio, and consulted for Almirall, BSN medical, Incyte, Janssen, Kymera, and XBiotech. Dr C.H. Smith is an investigator on Medical Research Council and Horizon 2020?funded consortia with industry partners (see psort.org.uk and biomap-imi.eu). Drs H.B. Naik (board member) and M.A. Lowes (vice president) are unpaid members of the US Hidradenitis Suppurativa Foundation. Drs L. Castelo-Soccio, K.M. Cordoro and I. Lara-Corrales are part of the PeDRA COVID-19 Response Task Force, a collaboration between the SPD and the PeDRA. Dr C. Flohr is President of the British Society for Paediatric Dermatology and Chief Investigator of the UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR) (ISRCTN11210918). Dr C. Flohr and the patient-facing part of the SECURE-AD registry are supported by the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas? NHS Foundation Trust, London, UK. Dr A.D. Irvine is the unpaid Chairman of National and International Skin Registry Solutions (NISR) Ltd, a not-for-profit charity dedicated to developing registries for patients with skin disease. NISR supports the Secure-AD registry. Dr A.D. Irvine is a co?principal investigator on the A-STAR and has been a consultant or speaker for Regeneron and LEO Pharma outside of the scope of the current work. Dr P.I. Spuls has received departmental independent research grants from a few pharmaceutical companies for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of conditions like psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital, and is chief investigator of a systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigators of the SECURE-AD registry. Drs D. Wall and R. Sinclair colead and are members of the steering committee, along with Dr N. Meah, of the SECURE-Alopecia registry. Drs R. Sinclair, D. Wall, and N. Meah are leading the development of the Global Registry of Alopecia Areata Disease Severity and Treatment Safety. Dr D. Wall is an employee of the charity NISR. Dr R. Sinclair also reports serving as a consultant or paid speaker for or participating in clinical trials sponsored by LEO Pharma, Amgen, Merck & Co, Celgene Corporation, Coherus BioSciences, Regeneron Pharmaceuticals, MedImmune, GlaxoSmithKline, Cutanea, Samson Clinical, Boehringer Ingelheim, Merck Sharpe & Dohme, Oncobiologics, F. Hoffman?La Roche, and Bayer AG and serves as the current president of the Australasian Hair and Wool Research Society. G.C. Chamberlin and D.E. McMahon and Drs E.A. Balogh and A.V. Marzano have no conflicts of interest to declare. Funding Information: Dr L.E. French is president of the ILDS. Dr E.E. Freeman is principal investigator of the AAD/ILDS COVID-19 Dermatology Registry. The ILDS provides financial support for the AAD/ILDS registry. Dr E.E. Freeman is an author for UpToDate. Drs S.R. Feldman, C.E.M. Griffiths, S.K. Mahil, H.B. Naik, and C.H. Smith have received funding or support from and Drs L.E. French, A.D. Irvine, and P.I. Spuls have been consultants for AbbVie; Dr M.A. Lowes has served on the advisory board for AbbVie. Drs S.R. Feldman, L.E. French, C.E.M. Griffiths, S.K. Mahil, R. Sinclair, and C.H. Smith have received funding or support from Novartis . Drs S.R. Feldman, C.E.M. Griffiths, R. Sinclair, C.H. Smith, and D. Wall have received funding from Pfizer . Drs S.R. Feldman, S.K. Mahil, and C.H. Smith have received funding from and Drs A.D. Irvine and P.I. Spuls have been consultants for Sanofi. Drs S.R. Feldman, C.E.M. Griffiths, A.D. Irvine, S.K. Mahil, R. Sinclair, and D. Wall have received funding or honoraria from Eli Lily ; Drs S.R. Feldman, L.E. French, C.E.M. Griffiths, S.K. Mahil, R. Sinclair, and D. Wall have received funding or honoraria from Janssen . Drs S.R. Feldman and C.E. M. Griffiths have received funding or support from BMS , Almirall , Amgen , Galderma , LEO Pharma , Stiefel GSK , and Sun Pharmaceuticals . Drs C.E.M. Griffiths and S.K. Mahil have received funding or support from Celgene and UCB Pharma . Dr C.E.M. Griffiths has received honoraria and/or research grants from MSD and Sandoz . Dr S.R. Feldman received research, speaking and/or consulting support from Alvotech, Boehringer Ingelheim, Mylan, Ortho Dermatology, Samsung, Menlo, Helsinn, Arena, Forte, Merck, Regeneron, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. Dr S.R. Feldman is founder and majority owner of www.DrScore.com and is founder and part owner of Causa Research, a company dedicated to enhancing patients{\textquoteright} adherence to treatment. Dr L.E. French received speaking and/or consulting support from Galderma, Amgen, Leo Pharma, Biotest, and Pincell Srl. Dr H.B. Naik has received consulting fees from 23andme, Abbvie, and DAVA Oncology and advisory board fees from Boehringer Ingelheim and is an investigator for Pfizer. She also is an associate editor for JAMA Dermatology. Dr M.A. Lowes has served on the advisory boards for Abbvie, InflaRx, Janssen, and Viela Bio, and consulted for Almirall, BSN medical, Incyte, Janssen, Kymera, and XBiotech. Dr C.H. Smith is an investigator on Medical Research Council and Horizon 2020–funded consortia with industry partners (see psort.org.uk and biomap-imi.eu). Drs H.B. Naik (board member) and M.A. Lowes (vice president) are unpaid members of the US Hidradenitis Suppurativa Foundation. Drs L. Castelo-Soccio, K.M. Cordoro and I. Lara-Corrales are part of the PeDRA COVID-19 Response Task Force, a collaboration between the SPD and the PeDRA. Dr C. Flohr is President of the British Society for Paediatric Dermatology and Chief Investigator of the UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR) (ISRCTN11210918). Dr C. Flohr and the patient-facing part of the SECURE-AD registry are supported by the National Institute for Health Research Biomedical Research Centre at Guy{\textquoteright}s and St Thomas{\textquoteright} NHS Foundation Trust, London, UK. Dr A.D. Irvine is the unpaid Chairman of National and International Skin Registry Solutions (NISR) Ltd, a not-for-profit charity dedicated to developing registries for patients with skin disease. NISR supports the Secure-AD registry. Dr A.D. Irvine is a co–principal investigator on the A-STAR and has been a consultant or speaker for Regeneron and LEO Pharma outside of the scope of the current work. Dr P.I. Spuls has received departmental independent research grants from a few pharmaceutical companies for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of conditions like psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital, and is chief investigator of a systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigators of the SECURE-AD registry. Drs D. Wall and R. Sinclair colead and are members of the steering committee, along with Dr N. Meah, of the SECURE-Alopecia registry. Drs R. Sinclair, D. Wall, and N. Meah are leading the development of the Global Registry of Alopecia Areata Disease Severity and Treatment Safety. Dr D. Wall is an employee of the charity NISR. Dr R. Sinclair also reports serving as a consultant or paid speaker for or participating in clinical trials sponsored by LEO Pharma, Amgen, Merck & Co, Celgene Corporation, Coherus BioSciences, Regeneron Pharmaceuticals, MedImmune, GlaxoSmithKline, Cutanea, Samson Clinical, Boehringer Ingelheim, Merck Sharpe & Dohme, Oncobiologics, F. Hoffman–La Roche, and Bayer AG and serves as the current president of the Australasian Hair and Wool Research Society. G.C. Chamberlin and D.E. McMahon and Drs E.A. Balogh and A.V. Marzano have no conflicts of interest to declare.",

year = "2021",

month = oct,

day = "1",

doi = "https://doi.org/10.1016/j.det.2021.05.013",

language = "English",

volume = "39",

pages = "575--585",

journal = "Dermatologic clinics",

issn = "0733-8635",

publisher = "W.B. Saunders Ltd",

number = "4",

}

Freeman, EE, Chamberlin, GC, McMahon, DE, Hruza, GJ, Wall, D, Meah, N, Sinclair, R, Balogh, EA, Feldman, SR, Lowes, MA, Marzano, AV, Naik, HB, Castelo-Soccio, L, Lara-Corrales, I, Cordoro, KM, Mahil, SK, Griffiths, CEM, Smith, CH, Irvine, AD, Spuls, PI, Flohr, C & French, LE 2021, 'Dermatology COVID-19 Registries: Updates and Future Directions', Dermatologic clinics, vol. 39, no. 4, pp. 575-585. https://doi.org/10.1016/j.det.2021.05.013

TY - JOUR

T1 - Dermatology COVID-19 Registries: Updates and Future Directions

AU - Freeman, Esther E.

AU - Chamberlin, Grace C.

AU - McMahon, Devon E.

AU - Hruza, George J.

AU - Wall, Dmitri

AU - Meah, Nekma

AU - Sinclair, Rodney

AU - Balogh, Esther A.

AU - Feldman, Steven R.

AU - Lowes, Michelle A.

AU - Marzano, Angelo V.

AU - Naik, Haley B.

AU - Castelo-Soccio, Leslie

AU - Lara-Corrales, Irene

AU - Cordoro, Kelly M.

AU - Mahil, Satveer K.

AU - Griffiths, Christopher E. M.

AU - Smith, Catherine H.

AU - Irvine, Alan D.

AU - Spuls, Phyllis I.

AU - Flohr, Carsten

AU - French, Lars E.

N1 - Funding Information: Dr L.E. French is president of the ILDS. Dr E.E. Freeman is principal investigator of the AAD/ILDS COVID-19 Dermatology Registry. The ILDS provides financial support for the AAD/ILDS registry. Dr E.E. Freeman is an author for UpToDate. Drs S.R. Feldman, C.E.M. Griffiths, S.K. Mahil, H.B. Naik, and C.H. Smith have received funding or support from and Drs L.E. French, A.D. Irvine, and P.I. Spuls have been consultants for AbbVie; Dr M.A. Lowes has served on the advisory board for AbbVie. Drs S.R. Feldman, L.E. French, C.E.M. Griffiths, S.K. Mahil, R. Sinclair, and C.H. Smith have received funding or support from Novartis. Drs S.R. Feldman, C.E.M. Griffiths, R. Sinclair, C.H. Smith, and D. Wall have received funding from Pfizer. Drs S.R. Feldman, S.K. Mahil, and C.H. Smith have received funding from and Drs A.D. Irvine and P.I. Spuls have been consultants for Sanofi. Drs S.R. Feldman, C.E.M. Griffiths, A.D. Irvine, S.K. Mahil, R. Sinclair, and D. Wall have received funding or honoraria from Eli Lily; Drs S.R. Feldman, L.E. French, C.E.M. Griffiths, S.K. Mahil, R. Sinclair, and D. Wall have received funding or honoraria from Janssen. Drs S.R. Feldman and C.E. M. Griffiths have received funding or support from BMS, Almirall, Amgen, Galderma, LEO Pharma, Stiefel GSK, and Sun Pharmaceuticals. Drs C.E.M. Griffiths and S.K. Mahil have received funding or support from Celgene and UCB Pharma. Dr C.E.M. Griffiths has received honoraria and/or research grants from MSD and Sandoz. Dr S.R. Feldman received research, speaking and/or consulting support from Alvotech, Boehringer Ingelheim, Mylan, Ortho Dermatology, Samsung, Menlo, Helsinn, Arena, Forte, Merck, Regeneron, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. Dr S.R. Feldman is founder and majority owner of www.DrScore.com and is founder and part owner of Causa Research, a company dedicated to enhancing patients? adherence to treatment. Dr L.E. French received speaking and/or consulting support from Galderma, Amgen, Leo Pharma, Biotest, and Pincell Srl. Dr H.B. Naik has received consulting fees from 23andme, Abbvie, and DAVA Oncology and advisory board fees from Boehringer Ingelheim and is an investigator for Pfizer. She also is an associate editor for JAMA Dermatology. Dr M.A. Lowes has served on the advisory boards for Abbvie, InflaRx, Janssen, and Viela Bio, and consulted for Almirall, BSN medical, Incyte, Janssen, Kymera, and XBiotech. Dr C.H. Smith is an investigator on Medical Research Council and Horizon 2020?funded consortia with industry partners (see psort.org.uk and biomap-imi.eu). Drs H.B. Naik (board member) and M.A. Lowes (vice president) are unpaid members of the US Hidradenitis Suppurativa Foundation. Drs L. Castelo-Soccio, K.M. Cordoro and I. Lara-Corrales are part of the PeDRA COVID-19 Response Task Force, a collaboration between the SPD and the PeDRA. Dr C. Flohr is President of the British Society for Paediatric Dermatology and Chief Investigator of the UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR) (ISRCTN11210918). Dr C. Flohr and the patient-facing part of the SECURE-AD registry are supported by the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas? NHS Foundation Trust, London, UK. Dr A.D. Irvine is the unpaid Chairman of National and International Skin Registry Solutions (NISR) Ltd, a not-for-profit charity dedicated to developing registries for patients with skin disease. NISR supports the Secure-AD registry. Dr A.D. Irvine is a co?principal investigator on the A-STAR and has been a consultant or speaker for Regeneron and LEO Pharma outside of the scope of the current work. Dr P.I. Spuls has received departmental independent research grants from a few pharmaceutical companies for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of conditions like psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital, and is chief investigator of a systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigators of the SECURE-AD registry. Drs D. Wall and R. Sinclair colead and are members of the steering committee, along with Dr N. Meah, of the SECURE-Alopecia registry. Drs R. Sinclair, D. Wall, and N. Meah are leading the development of the Global Registry of Alopecia Areata Disease Severity and Treatment Safety. Dr D. Wall is an employee of the charity NISR. Dr R. Sinclair also reports serving as a consultant or paid speaker for or participating in clinical trials sponsored by LEO Pharma, Amgen, Merck & Co, Celgene Corporation, Coherus BioSciences, Regeneron Pharmaceuticals, MedImmune, GlaxoSmithKline, Cutanea, Samson Clinical, Boehringer Ingelheim, Merck Sharpe & Dohme, Oncobiologics, F. Hoffman?La Roche, and Bayer AG and serves as the current president of the Australasian Hair and Wool Research Society. G.C. Chamberlin and D.E. McMahon and Drs E.A. Balogh and A.V. Marzano have no conflicts of interest to declare. Funding Information: Dr L.E. French is president of the ILDS. Dr E.E. Freeman is principal investigator of the AAD/ILDS COVID-19 Dermatology Registry. The ILDS provides financial support for the AAD/ILDS registry. Dr E.E. Freeman is an author for UpToDate. Drs S.R. Feldman, C.E.M. Griffiths, S.K. Mahil, H.B. Naik, and C.H. Smith have received funding or support from and Drs L.E. French, A.D. Irvine, and P.I. Spuls have been consultants for AbbVie; Dr M.A. Lowes has served on the advisory board for AbbVie. Drs S.R. Feldman, L.E. French, C.E.M. Griffiths, S.K. Mahil, R. Sinclair, and C.H. Smith have received funding or support from Novartis . Drs S.R. Feldman, C.E.M. Griffiths, R. Sinclair, C.H. Smith, and D. Wall have received funding from Pfizer . Drs S.R. Feldman, S.K. Mahil, and C.H. Smith have received funding from and Drs A.D. Irvine and P.I. Spuls have been consultants for Sanofi. Drs S.R. Feldman, C.E.M. Griffiths, A.D. Irvine, S.K. Mahil, R. Sinclair, and D. Wall have received funding or honoraria from Eli Lily ; Drs S.R. Feldman, L.E. French, C.E.M. Griffiths, S.K. Mahil, R. Sinclair, and D. Wall have received funding or honoraria from Janssen . Drs S.R. Feldman and C.E. M. Griffiths have received funding or support from BMS , Almirall , Amgen , Galderma , LEO Pharma , Stiefel GSK , and Sun Pharmaceuticals . Drs C.E.M. Griffiths and S.K. Mahil have received funding or support from Celgene and UCB Pharma . Dr C.E.M. Griffiths has received honoraria and/or research grants from MSD and Sandoz . Dr S.R. Feldman received research, speaking and/or consulting support from Alvotech, Boehringer Ingelheim, Mylan, Ortho Dermatology, Samsung, Menlo, Helsinn, Arena, Forte, Merck, Regeneron, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. Dr S.R. Feldman is founder and majority owner of www.DrScore.com and is founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. Dr L.E. French received speaking and/or consulting support from Galderma, Amgen, Leo Pharma, Biotest, and Pincell Srl. Dr H.B. Naik has received consulting fees from 23andme, Abbvie, and DAVA Oncology and advisory board fees from Boehringer Ingelheim and is an investigator for Pfizer. She also is an associate editor for JAMA Dermatology. Dr M.A. Lowes has served on the advisory boards for Abbvie, InflaRx, Janssen, and Viela Bio, and consulted for Almirall, BSN medical, Incyte, Janssen, Kymera, and XBiotech. Dr C.H. Smith is an investigator on Medical Research Council and Horizon 2020–funded consortia with industry partners (see psort.org.uk and biomap-imi.eu). Drs H.B. Naik (board member) and M.A. Lowes (vice president) are unpaid members of the US Hidradenitis Suppurativa Foundation. Drs L. Castelo-Soccio, K.M. Cordoro and I. Lara-Corrales are part of the PeDRA COVID-19 Response Task Force, a collaboration between the SPD and the PeDRA. Dr C. Flohr is President of the British Society for Paediatric Dermatology and Chief Investigator of the UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR) (ISRCTN11210918). Dr C. Flohr and the patient-facing part of the SECURE-AD registry are supported by the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust, London, UK. Dr A.D. Irvine is the unpaid Chairman of National and International Skin Registry Solutions (NISR) Ltd, a not-for-profit charity dedicated to developing registries for patients with skin disease. NISR supports the Secure-AD registry. Dr A.D. Irvine is a co–principal investigator on the A-STAR and has been a consultant or speaker for Regeneron and LEO Pharma outside of the scope of the current work. Dr P.I. Spuls has received departmental independent research grants from a few pharmaceutical companies for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of conditions like psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital, and is chief investigator of a systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigators of the SECURE-AD registry. Drs D. Wall and R. Sinclair colead and are members of the steering committee, along with Dr N. Meah, of the SECURE-Alopecia registry. Drs R. Sinclair, D. Wall, and N. Meah are leading the development of the Global Registry of Alopecia Areata Disease Severity and Treatment Safety. Dr D. Wall is an employee of the charity NISR. Dr R. Sinclair also reports serving as a consultant or paid speaker for or participating in clinical trials sponsored by LEO Pharma, Amgen, Merck & Co, Celgene Corporation, Coherus BioSciences, Regeneron Pharmaceuticals, MedImmune, GlaxoSmithKline, Cutanea, Samson Clinical, Boehringer Ingelheim, Merck Sharpe & Dohme, Oncobiologics, F. Hoffman–La Roche, and Bayer AG and serves as the current president of the Australasian Hair and Wool Research Society. G.C. Chamberlin and D.E. McMahon and Drs E.A. Balogh and A.V. Marzano have no conflicts of interest to declare.

PY - 2021/10/1

Y1 - 2021/10/1

KW - Atopic dermatitis

KW - COVID-19

KW - Dermatology

KW - Global health

KW - Hidradenitis suppurativa

KW - Psoriasis

KW - Registry

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85115305645&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.det.2021.05.013

DO - https://doi.org/10.1016/j.det.2021.05.013

M3 - Review article

C2 - 34556247

SN - 0733-8635

VL - 39

SP - 575

EP - 585

JO - Dermatologic clinics

JF - Dermatologic clinics

IS - 4

ER -

Dermatology COVID-19 Registries: Updates and Future Directions

Keywords

Access to Document

Other files and links

Cite this